January 25, 2012
Special Committee Of Helix BioPharma Corp. Provides Update To Shareholders
January 23, 2012
Helix BioPharma Corp. Announces that Institutional Shareholder Services
Recommends Shareholders Vote for Management’s Director Nominees
January 23, 2012
Helix BioPharma Corp. Responds To Dissident Proxy Circular In Connection With The January 30, 2012 Shareholder
Meeting
January 13, 2012
Helix BioPharma Corp. Announces Q1 2012 Results
Helix BioPharma Corporation is developing innovative products for the prevention and treatment of cancer based on its proprietary technologies.
Helix is focused on the development of two product candidates: The Company’s most advanced initiative is its Topical Interferon Alpha-2b that employs, Biphasix, Helix's proprietary drug delivery technology. Topical Interferon Alpha-2b has undergone clinical testing for the treatment of potentially precancerous, low-grade cervical lesions and ano-genital warts, both of which are conditions caused by human papillomavirus (HPV) infections. Helix is currently focusing its Topical Interferon Alpha-2b development resources on the low-grade cervical lesion indication.
Helix’s second initiative is its L-DOS47 for the treatment of inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). L-DOS47 is based upon Helix’s patented platform technology, DOS47, for the destruction of cancer cells.
Helix is headquartered in Toronto, Canada and listed on the Toronto Stock Exchange (TSX), NYSE Amex and Frankfurt Stock Exchange (FSE) under the symbol: HBP.
Topical Interferon Alpha-2b
Background and Phase II Program Click here for more information.
L-DOS47
What is L-DOS47? Learn more about Helix's potential cancer therapeutic. Click Here for more information.
